Optimized Cord Blood Transplant for Relapsed Hematologic Malignancies
This study is for patients aged 0-60 who have high-risk blood cancers (hematologic malignancies) that have returned more than 100 days after their first stem cell transplant. The goal is to see if a cord blood transplant, given after a specific type of chemotherapy (intermediate-intensity conditioning therapy), can help control the cancer. The chemotherapy drugs used are Cyclophosphamide, Fludarabine, Thiotepa, Tacrolimus, and Mycophenolate mofetil. Researchers will be looking at how safe this treatment is and any side effects you might experience. The study plans to enroll 35 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 35 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and side effects will be measured through study completion, which is an average of 1 year. Other outcomes will be tracked for up to 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Warren Fingrut, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and Adverse Events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0